fbpx Skip to content


Cure For Peanut Allergies On the Horizon

| Earn 1 CEC - Take Quiz

Peanut allergies affect 2% of U.S. children and are the leading cause of death by food allergies. Unlike many of them, peanut allergies are rarely outgrown, and there are currently no treatments. People with peanut allergies must scrutinize everything they eat and keep a lifesaving epinephrine injection pen on hand in case of an accidental exposure.

Pharmaceutical companies are racing to develop an FDA-approved treatment that will effectively desensitize peanut allergy, causing the immune system to chill out and not react hysterically to peanut protein exposure. News articles in February reported that the drug company Aimmune Therapeutics succeeded in a phase 3 clinical trial and is closing in on getting an approved treatment to market.

Aimmune’s oral drug, called AR101, contains tiny doses of peanut protein that are sprinkled daily over food to expose people to gradually increasing amounts of the allergen. This makes the immune cells less reactive, ultimately blunting the immune response to peanut protein.

A clinical trial showed that 67% of 4- to 17-year-olds who received the drug could tolerate a 600-milligram dose of peanut protein by the end of the study, compared with 4% of patients on a placebo. The positive trial enables Aimmune to apply for FDA approval, which the company says it plans to do by the end of 2018.

Natalie Digate Muth, MD, MPH, RD

"Natalie Digate Muth, MD, MPH, RDN, FAAP, is a board-certified pediatrician and obesity medicine physician, registered dietitian and health coach. She practices general pediatrics with a focus on healthy family routines, nutrition, physical activity and behavior change in North County, San Diego. She also serves as the senior advisor for healthcare solutions at the American Council on Exercise. Natalie is the author of five books and is committed to helping every child and family thrive. She is a strong advocate for systems and communities that support prevention and wellness across the lifespan, beginning at 9 months of age."

Related Articles

When you buy something using the retail links in our content, we may earn a small commission. IDEA Health and Fitness Association does not accept money for editorial reviews. Read more about our Terms & Conditions and our Privacy Policy.


November-December 2020 IDEA Fitness Journal

Concerned about your place in the new fitness industry? We have 40 years of experience supporting pros just like you! Let’s create a new wellness paradigm together—IDEAfit+ is the extra edge you need. Once you team up with IDEA, be sure to take full advantage of all the benefits of membership.